Citi analyst Yigal Nochomovitz raised his price target for Reata Pharmaceuticals to $185 from $95 and added the stock to his firm’s US Focus List. The shares closed yesterday up 40c to $76.95. The analyst also elevated Reata to the Top Pick in his SMID Biotech coverage space. The analyst added among rare nephropathies into his model following the company’s “exceptional data” reported early this week in Alport syndrome. He now has “solid confidence” for bardoxolone methyl in other rare nephropathies. Autosomal dominant polycystic kidney disease is the most substantial market among the rare nephropathies in the analyst’s model. Nochomovitz keeps a Buy rating on Reata.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.